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Abstract. Antimalarial resistance to sulfadoxine-pyrimethamine (SP) is mediated by mutations in the dihydrofolate
reductase (dhfr) and dihydropteroate synthase (dhps) genes. However, the relative importance of different mutations is
incompletely understood and has not been studied with combination therapy. Samples from 812 patients treated for
uncomplicated malaria in Kampala, Uganda were tested for the presence of mutations commonly found in Africa. The
dhps Glu-540 mutation was the strongest independent predictor of treatment failure. The dhfr Arg-59 mutation was only
predictive of treatment failure in the presence of the dhps Glu-540 mutation. Comparing combination regimens with SP
monotherapy, the addition of chloroquine to SP did not improve efficacy, the addition of artesunate lowered the risk of
treatment failure only for infections with both the dhfr Arg-59 and dhps Glu-540 mutations, and the addition of
amodiaquine lowered this risk for all dhfr/dhps mutation patterns. The dhps Glu-540 mutation played a principal role
and the dhfr Arg-59 mutation a secondary role in mediating resistance to SP alone and in combination.
INTRODUCTION
Sulfadoxine-pyrimethamine (SP) is currently the first-line
antimalarial therapy in several African countries where chlo-
roquine (CQ) resistance is widespread and other drugs re-
main too expensive for general use.1 It is generally regarded
as a single antimalarial agent because its success depends on
the synergistic action of its two component inhibitors of folate
synthesis.2 Resistance to SP spread rapidly in southeast Asia
following widespread use3 and is now spreading in Africa.4 In
an attempt to improve treatment efficacy and delay the
spread of drug resistance, several countries in Africa recently
changed to inexpensive combinations of SP plus CQ or amo-
diaquine (AQ) as first-line antimalarial therapy.1 In addition,
many authorities advocate combinations with artesunate
(AS) or other artemisinins, including SP plus AS,5 although
these regimens are expensive.
Resistance to SP is caused by point mutations that accu-
mulate at several sites in the dihydrofolate reductase (dhfr)
and dihydropteroate synthase (dhps) genes, resulting in in-
creasing degrees of drug resistance in vitro.2,6 For dhfr, a
point mutation at position 108 (Ser→Asn) increases resis-
tance to pyrimethamine approximately 100-fold.7 The addi-
tion of mutations at positions 51 (Asn→Ile) and 59
(Cys→Arg) progressively enhances in vitro resistance to py-
rimethamine.2 The relationship between dhps mutations and
in vitro resistance to sulfadoxine is less clear, in part because
the in vitro measurement of sulfadoxine activity is complex
due to differences in assay conditions and variations in the
ability of different parasite strains to use exogenous
folate.2,6,8 Nevertheless, it appears that in vitro resistance to
sulfadoxine is associated with accumulation of point muta-
tions in the dhps gene.9
Assessment of molecular markers of SP resistance has been
proposed as a means of monitoring in vivo drug resistance.
However, many questions remain about the relationship be-
tween dhfr and dhps mutations that confer in vitro resistance
and clinical treatment outcomes. The dhfr Asn-108 mutation
alone does not appear to be sufficient to confer clinical drug
resistance.10 The dhfr triple mutant (Asn-108 + Ile-51 + Arg-
59) has been suggested as a useful predictor of treatment
failure by some investigators,11,12 although others have not
found useful predictive value for this genotype.13,14 Others
have suggested that the most useful predictor of SP treatment
failure is a combination of the dhfr triple mutant and two
dhps mutations (Gly-437 + Glu-540).15,16 A better under-
standing of the relationship of key dhfr and dhps mutations in
field isolates and of the independent roles of each mutation in
mediating response to therapy will be helpful in directing the
rational use of SP and SP-containing combination regimens.
In this study, we evaluated the relationship between key
dhfr and dhps mutations in a large sample of patients (n 
812) with uncomplicated Plasmodium falciparum malaria
from three clinical trials conducted over a five-year period in
Kampala, Uganda. In addition, we evaluated combinations of
dhfr and dhps alleles to identify the strongest predictors of
treatment failure, and we compared the relationship between
allelic risk groups and response to SP monotherapy and three
SP combination therapies (SP + CQ, SP + AQ, and SP + AS).
MATERIALS AND METHODS
Study site and subjects. All studies were conducted be-
tween March 1999 and June 2003 at the outpatient depart-
ment of Mulago Hospital in Kampala, the urban capital of
Uganda. Malaria is mesoendemic in Kampala, with peak
transmission occurring during two rainy seasons (Ugandan
Ministry of Health, unpublished data). Patients included in
this analysis came from three previously published clinical
trials. The treatment arms and study dates are as follows:
study 1; CQ versus SP, March 1999 to August 199917; study 2;
SP versus SP + AQ versus SP + AS, July 2000 to August
200118; and study 3; SP + CQ versus SP + AQ versus AQ +
AS, August 2002 to July 2003 (Staedke SG, unpublished
data). Only patients enrolled in SP monotherapy arms or SP
combination therapy arms (SP + CQ, SP + AQ, or SP + AS)
fulfilling the following selection criteria were included in this
study: 1) age range  6 months to 10 years, 2) tympanic
temperature  38°C or a history of fever in the previous 48
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hours, 3) absence of severe malaria19 or danger signs (inabil-
ity to stand or drink, lethargy, recent convulsions, persistent
vomiting), 4) willingness to provide informed consent, 5) resi-
dence within Kampala 6) P. falciparum mono-infection, 7)
parasite density  500 asexual parasites/L, and 8) successful
outcome classification after 28 days of follow-up, adjusted for
genotyping.
Informed consent was obtained from all adult participants
and from parents or legal guardians of minors. All protocols
were reviewed and approved by the Institutional Review
Boards of Makerere University, Kampala and the University
of California, San Francisco.
Patient follow-up and outcome classification. Standardized
clinical outcomes for all subjects were assessed using the 1996
World Health Organization (WHO) clinical classification sys-
tem (adequate clinical response [ACR], early treatment fail-
ure [ETF], or late treatment failure [LTF])20 with follow-up
extended to 28 days and the modification that after day 3,
patients with parasitemia and a history of recent fever (not
documented) were considered LTF. For subjects with recur-
rent parasitemia after day 4, pretreatment samples and
samples from the day of treatment failure were analyzed for
polymorphisms in merozoite surface protein 2 to distinguish
recrudescence from new infections, according to previously
published methods.21 Genotyping was successful in 97% of
the samples analyzed. For the purposes of this study, treat-
ment failure was defined as fulfillment of the WHO criteria
for ETF or LTF in the presence of recrudescent parasites.
Mutation analysis. The presence of dhfr Asn-108, Ile-51,
and Arg-59 and dhps Gly-437 and Glu-540 mutations com-
monly found in Africa were determined using a nested poly-
merase chain reaction amplification followed by restriction
enzyme digestion. All five mutations were assessed in the SP
monotherapy group and only the dhfr Arg-59 and dhps Gly-
437 and Glu-540 mutations were assessed in the combina-
tion therapy groups. Blood was collected on filter paper on
the day of diagnosis and parasite DNA isolated using the
Chelex extraction method.22 Primers, amplification condi-
tions, and restriction endonucleases for assays to detect all
mutations were as previously described.15,23 Digestion
products were visualized by gel electrophoresis and results
were classified as wild-type, pure mutant, or mixed (both
wild-type and mutant alleles present in the same infection)
based on the migration patterns of the fragments. Investiga-
tors were blinded to clinical outcomes at the time of molecu-
lar analysis.
Statistical analysis. Associations between categorical vari-
ables were assessed using the chi-square or Fisher’s exact test
as appropriate. Associations between combinations of dhfr
and dhps mutations and treatment failure were assessed using
multivariate logistic regression, controlling for age and para-
site density, with treatment and allelic risk groups included as
interaction terms. All interaction terms with P values  0.2
were retained in the final model. Graphic presentation of the
change in the prevalence of mutations over calendar time was
generated using the lowess locally weighted regression
smoothing technique. Parasite density was normalized using
natural log transformation. All data were entered and verified
using Epi-Info version 6.04 (Centers for Disease Control and
Prevention, Atlanta, GA) and SPSS (SPSS Inc., Chicago, IL).
Analysis was performed using STATA statistical software
(Stata Corp., College Station, TX). All confidence levels were
set at 95%. Data on the association between molecular mark-
ers of SP resistance and clinical outcomes in the SP mono-
therapy group have been published previously,15,24 but were
included in this study to improve statistical power and provide
a comparison group for the SP-combination therapies.
RESULTS
Patient characteristics and treatment outcomes. A total of
812 subjects from 4 different treatment groups enrolled be-
tween March 1999 and April 2003 were included in this study.
Compared with the SP monotherapy group (32%), the risk of
treatment failure at 28 days was similar in the SP + CQ group
(35%; P 0.58) and significantly lower in the SP + AS (17%;
P 0.0003) and SP + AQ (7%; P < 0.0001) groups (Table 1).
Prevalence and relationship of dhfr and dhps muta-
tions. We were interested in the prevalence of key dhfr
(Asn-108, Ile-51, and Arg-59) and dhps mutations (Gly-437
and Glu-540) and the relationship between these mutations.
A total of 2,832 (97%) of 2,930 molecular assays were suc-
cessfully performed for dhfr Asn-108 and Ile-51 mutations in
the SP monotherapy group and for dhfr Arg-59 and dhps
Gly-437 and Glu-540 mutations in all treatment groups. The
dhfr Asn-108 and Ile-51 mutations were very common, with
88% and 91% of samples having the pure mutant and 97%
and 94% having a mixed or pure mutant, respectively (Figure
1). The dhfr Arg-59 mutation occurred less commonly and
was strongly linked to the dhfr Asn-108 and Ile-51 mutations.
Of the 161 samples that were mixed or pure mutant for dhfr
Arg-59, only 3 (2%) were wild-type for dhfr Asn-108, 6 (4%)
TABLE 1
Baseline characteristics and treatment outcomes
Treatment group*
SP SP + CQ SP + AS SP + AQ
Number of subjects 247 125 173 267
Studies (n) and enrollment period† Study 1 (63) Study 3 (125) Study 2 (173) Study 2 (138)
Study 2 (184) Study 3 (129)
Median age in years (range) 3.1 (0.5–10) 4.3 (0.5–10) 3.1 (0.6–5.7) 3.1 (0.5–10)
Geometric mean parasite density (per l) 35,027 24,191 52,727 36,446
Early treatment failure‡ (%) 25 (10%) 2 (2%) 0 5 (2%)
Late treatment failures§ (%) 55 (22%) 42 (34%) 29 (17%) 14 (5%)
* SP  sulfadoxine/pyrimethamine; CQ  chloroquine; AS  artesunate; AQ  amodiaquine.
† Study 1 March 1999–August 1999; Study 2 July 2000–August 2001; Study 3 August 2002–April 2003.
‡ Treatment failure on days 1–3.
§ Treatment failure on days 4–28 adjusted by genotyping.
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were wild-type for dhfr Ile-51, and none were wild-type for
both. The prevalences of the dhps Gly-437 and Glu-540 mu-
tations were 61% and 62% for the pure mutant and 80% and
81% for the mixed or pure mutant, respectively (Figure 1).
The dhps Gly-437 and Glu-540 alleles were strongly linked,
with 641 (82%) of 778 samples having the same result and
only 56 (7%) of 778 samples wild-type for one dhps allele and
mixed or pure mutant for the other. Considering relationships
between mutations in different genes, there was a significant
association between the dhfr Arg-59 and dhps Glu-540 mu-
tations (P < 0.001). However, 94 (12%) of 782 samples con-
tained the dhfr Arg-59 mutation in the absence of the dhps
Glu-540 mutation and 181 (23%) of 782 samples contained
the dhps Glu-540 in the absence of the dhfr Arg-59 mutation.
Thus, it was not uncommon for the dhps Glu-540 mutation to
occur in the absence of the dhfr Arg-59 mutation.
Association between dhfr and dhps alleles and treat-
ment outcomes. To maximize our sample size, we pooled the
treatment groups from our three clinical studies and evalu-
ated the association between dhfr and dhps alleles and re-
sponse to therapy. To simplify our analysis, we focused only
on those alleles that were independent predictors of treat-
ment outcome. Given the very high prevalence of the dhfr
Asn-108 and Ile-51 mutations and their almost ubiquitous
presence in the setting of the dhfr Arg-59 mutation, results at
the dhfr 108 and 51 alleles did not add to the predictive value
of the dhfr 59 allele alone and were thus not assessed for
combination therapy groups. Given the strong association be-
tween the dhps 437 and 540 alleles, we evaluated their indi-
vidual predictive values. Considering samples that were dhps
Gly-437 mixed or pure mutant and dhps 540 wild-type, only 1
(4%) of 23 resulted in treatment failure. In contrast, consid-
ering samples that were dhps Glu-540 mixed or pure mutant
and dhps 437 wild-type, 8 (24%) of 33 resulted in treatment
failure. Based on these findings, we concluded that results for
the dhps 437 allele did not add to the predictive value of the
dhps 540 allele alone.
Since dhfr 108 and 51 alleles and the dhps 437 allele were
not independent predictors, further analyses concentrated on
the association between dhfr 59 and dhps 540 alleles and
treatment outcomes. Our goal was to identify patterns that
best predicted treatment outcomes based on all possible com-
binations of these two alleles. In this and all subsequent analy-
ses, ETFs were excluded because we previously showed that
molecular markers of SP resistance were not associated with
ETFs15; others have suggested that many ETFs are due to
slow clearance of parasites without true parasite resistance.16
Risk of treatment failure was assessed based on dhfr 59 and
dhps 540 alleles. For samples containing the dhps 540 wild-
type allele (termed the low-risk allelic group), the risk of
treatment failure was low (6 of 143, 4%), and this risk was not
significantly different across strata based on dhfr 59 alleles
(P  0.38) (Table 2). For samples containing the dhps Glu-
540 mixed or pure mutant allele, but excluding dhfr Arg-59 +
dhps Glu-540 pure mutants (termed the intermediate-risk al-
lelic group), the risk of treatment failure was significantly
higher (58 of 327, 18%) compared with the low-risk group (P
 0.0001). Again, there was no significant difference in the
risk of treatment failure for this group across strata based on
dhfr 59 alleles (P  0.80) (Table 2). For samples containing
both the dhfr Arg-59 and dhps Glu-540 pure mutants (termed
the high-risk allelic group), the risk of treatment failure was
significantly higher (76 of 283, 27%) compared with the low
risk (P < 0.0001) and the intermediate risk allelic groups (P
0.007). Thus, the presence of the dhfr Arg-59 mutation had an
independent effect on the risk of treatment failure only in the
presence of the dhps Glu-540 pure mutant. In contrast, the
presence of the dhps Glu-540 mutation had an independent
effect on the risk of treatment failure even in the absence of
the dhfr Arg-59 mutation.
Interestingly, the prevalence of the dhfr Arg-59 and dhps
Glu-540 pure mutants increased over the four-year period
during which samples were collected (Figure 2). The average
prevalence of the dhfr Arg-59 pure mutant increased from
40% in 1999 to 60% in 2003 and the average prevalence of the
dhps Glu-540 pure mutant increased from 40% in 1999 to
70% in 2003.
Association between dhfr and dhps alleles and treatment
outcomes stratified by treatment group. For SP monotherapy,
the risk of treatment failure was 7% for the low-risk allelic
group, 23% for the intermediate-risk group, and 37% for the
high-risk group (Figure 3). When age and pretreatment para-
site density were controlled, differences in these associations
were statistically significant (intermediate- versus low-risk al-
lelic groups, odds ratio [OR]  6.3, P < 0.001; high- versus
low-risk allelic groups, OR  14.4, P < 0.001) (Table 3).
Compared with SP monotherapy, SP + CQ combination
therapy was associated with a similar relationship between
the dhfr 59 and dhps 540 allelic risk groups and the risk of
treatment failure (Figure 3 and Table 3). Combining AS with
FIGURE 1. Prevalence of key dihydrofolate reductase (dhfr) and
dihydropteroate synthetase (dhps) mutations for all treatment groups
combined.
TABLE 2







treatment failure† Assigned risk group
Wild Wild 52 2% Low-risk group‡
Mixed Wild 22 9%
Mutant Wild 69 4%
Wild Mixed 41 20% Intermediate-risk group§
Mixed Mixed 61 21%
Mutant Mixed 43 19%
Wild Mutant 135 16%
Mixed Mutant 47 17%
Mutant Mutant 283 27% High-risk group¶
* dhfr  dihydrofolate reductase; dhps  dihydropteroate synthase.
† Treatment failure on days 4–28 adjusted by genotyping.
‡ Low-risk group  dhfr 59 any genotype and dhps 540 wild-type.
§ Intermediate-risk group  dhps Glu-540 mixed or pure mutant (excluding high-risk
group).
¶ High-risk group  dhfr Arg-59 pure mutant and dhps Glu-540 pure mutant.
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SP resulted in an overall reduction in the risk of treatment
failure (Figure 3), and the association between dhfr Arg-59
and dhps Glu-540 mutations and treatment failure remained
statistically significant (Table 3). However, samples from the
intermediate and high-risk groups had similar risks of treat-
ment failure (OR 6.3, P < 0.001 and OR 5.3, P 0.002,
respectively). Combining AQ with SP also resulted in an
overall reduction in the risk of treatment failure (Figure 3);
however, compared with samples from the low-risk allelic
group, only samples from the high-risk allelic group were
associated with treatment failure (OR  2.8, P  0.06)
(Table 3). The associations between dhfr and dhps allelic risk
groups and treatment outcomes presented in Table 3 were not
significantly different across different age groups (i.e., there
was no evidence of effect modification by age).
DISCUSSION
In this study, we investigated the relationship between key
dhfr and dhps mutations found in Africa and clinical response
to SP therapy alone and in combination with other drugs. We
developed a simplified predictive model of treatment re-
sponse based only on the presence of the dhfr Arg-59 and
dhps Glu-540 mutations, largely due to the fact that the pres-
ence of these mutations was highly predictive of the dhfr
triple mutant (Asn-108 + Ile-51 + Arg-59) and the dhps
double mutant (Gly-437 + Glu-540), respectively. Consider-
ing all treatment groups combined, the presence of the dhps
Glu-540 mutation was a much stronger predictor of clinical
treatment failure than the dhfr Arg-59 mutation. Indeed, the
dhfr Arg-59 mutation was only an independent predictor of
treatment failure in the presence of the dhps Glu-540 pure
mutant. Compared with SP monotherapy, the addition of CQ
to SP did not improve the risk of treatment failure after con-
trolling for the prevalence of the dhfr/dhps allelic risk groups.
The addition of AS to SP only lowered the risk of treatment
failure due to parasites containing both the dhfr Arg-59 and
dhps Glu-540 pure mutants. The addition of AQ to SP low-
ered the risk of treatment failure for all dhfr/dhps allelic risk
groups, and for this combination therapy treatment failure
was only associated with the dhfr Arg-59 + dhps Glu-540 pure
mutant.
Several studies from Africa have examined the relationship
between key dhfr and dhps mutations in field isolates. With
respect to dhfr mutations, it has been proposed that the se-
lection of mutations occurs in a stepwise fashion, first with the
selection of the Asn-108 mutation, followed by the selection
of mutations Ile-51 and/or Arg-59.25 Data on the selection of
dhps mutations is less clear. Some studies have reported the
presence of the dhps Gly-437 mutation in the absence of the
Glu-540 mutation12,26 or the presence of the Glu-540 muta-
tion only in combination with the Gly-437 mutation,27 sug-
gesting that the Gly-437 mutation is selected first.25 However,
the presence of the dhps Glu-540 mutation in the absence of
the Gly-437 mutation has been reported, although it appears
to be uncommon,16 as was the case in our study. It has been
further suggested that common dhfr and dhps mutations have
arisen independently on numerous occasions, with the incre-
mental selection of increasingly resistant parasites over
FIGURE 3. Treatment failure defined as a late treatment failure on
days 4−28 adjusted by genotyping. SP sulfadoxine-pyrimethamine,
CQ chloroquine, AQ amodiaquine, AS artesunate. Low-risk
group  dihydrofolate reductase (dhfr) 59 any genotype and dihy-
dropteroate synthetase (dhps) 540 wild-type; intermediate-risk group
 dhps Glu-540 mixed or pure mutant (excluding high-risk group);
high-risk group  dhfr Arg-59 pure mutant and dhps Glu-540 pure
mutant.
FIGURE 2. Change in average prevalence of dihydrofolate reduc-
tase (dhfr) Arg-59 and dihydropteroate synthetase (dhps) Glu-540
pure mutants over the duration of the three clinical trials using the
lowess locally weighted regression smoothing technique. Study 1 (sul-
fadoxine-pyrimethamine [SP] monotherapy), March 1999 to August
1999; study 2 (SP monotherapy, SP plus amodiaquine [AQ] and SP +
artesunate [AS]), July 2000 to August 2001; study 3 (SP plus CQ and
SP plus AQ), August 2002 to July 2003.
TABLE 3
Association between dhfr 59 and dhps 540 alleles and late treatment
failure for each treatment group*
dhfr/dhps Allelic group Treatment group OR (95% CI)† P
Low-risk group‡ All 1.0 (reference) –
Intermediate-risk group§ SP 6.3 (2.6–15.5) < 0.001
SP + CQ 13.0 (4.7–35.7) < 0.001
SP + AS 6.3 (2.6–15.5) < 0.001
SP + AQ 0.63 (0.2–2.6) 0.53
High risk-group¶ SP 14.4 (5.6–36.7) < 0.001
SP + CQ 23.8 (8.7–65.5) < 0.001
SP + AS 5.3 (1.8–15.3) 0.002
SP + AQ 2.8 (1.0–8.0) 0.06
* dhfr  dihydrofolate reductase; dhps  dihydropteroate synthase; SP  sulfadoxine/
pyrimethamine; CQ  chloroquine; AS  artesunate; AQ  amodiaquine.
† Multivariate logistic regression controlling for age and pretreatment parasite density
including significant interaction terms based on treatment and allelic risk groups OR odds
ratio; CI  confidence interval.
‡ Low-risk group  dhfr 59 any genotype and dhps 540 wild-type.
§ Intermediate-risk group  dhps Glu-540 mixed or pure mutant (excluding high-risk
group).
¶ High-risk group  dhfr Arg-59 pure mutant and dhps Glu-540 pure mutant.
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time.28 However, recent data from South Africa and Tanzania
demonstrated that gene flow, rather than the spontaneous
generation of new mutations, has been the most common
originator of SP resistance.4 In that study, a period of rapid
deterioration of SP efficacy was linked to a high background
prevalence of a single dhfr triple mutant allele (Asn-108 +
Ile-51 + Arg-59), followed by the spread of a single dhps
double mutant allele (Gly-437 + Glu-540), each derived from
independent ancestral lineages. The findings from our study
of strong linkage between the three dhfr mutations and, in-
dependently, between the two dhps mutations, which were
substantially increasing in prevalence over the four-year span
of our studies in Uganda, are consistent with this more recent
understanding of the basis of spread of SP resistance.
The relative importance of dhfr versus dhps mutations in
mediating treatment failure to SP has not been clearly re-
solved. In Cameroon, the dhfr triple mutant was associated
with 7 (100%) of 7 treatment failures, but was also present in
26 (44%) of 59 treatment successes.12 In Gabon, the dhfr
triple mutant was associated with 9 (82%) of 11 treatment
failures, but was also present in 51 (72%) of 71 treatment
successes.14 In both of these studies, there was no clear asso-
ciation between dhps mutations and treatment failure, but
importantly the dhps Glu-540 mutation was not detected at
either site and despite the high prevalence of the dhfr triple
mutant (50-73%), the 28-day risk of SP treatment failure was
less than 15%. In studies from east Africa, where the reported
risk of SP treatment failure is higher than in west Africa,
infection with parasites containing both the dhfr triple mutant
(Asn-108 + Ile-51 + Arg-59) and the dhps double mutant
(Gly-437 + Glu-540) was associated with the highest risk of
treatment failure.16,27 However, due to relatively small
samples sizes (n < 100) and the highly concordant nature of
dhfr and dhps mutations in field isolates, previous studies
have had limited power to evaluate independent associations
between these mutations and treatment response. In our
study, which benefited from a much larger sample size, we
found that the dhps Glu-540 mutation (a surrogate marker of
the Gly-437 + Glu-540 double mutant) was a strong predictor
of treatment failure independent of the dhfr Arg-59 mutation
(a surrogate marker of the Asn-108 + Ile-51 + Arg-59 triple
mutant). In addition, it was not uncommon (23% of the
samples) for the dhps Glu-540 mutation to occur in the ab-
sence of the dhfr Arg-59 mutation, contradicting previous
suggestions that key dhps mutations are rare in the absence of
the dhfr triple mutant.2 In contrast, the dhfr Arg-59 mutation
was associated with treatment failure only in the presence of
the dhps Glu-540 mutation. These results are consistent with
recent findings from South Africa, where five years after the
establishment of the dhfr triple mutant, an increase in the risk
of SP treatment failure from 20% to 70% coincided with the
emergence of the dhps double mutant.4
A recent detailed report summarized all known Ugandan
drug efficacy studies from 1988 to 2000, many of which were
previously unpublished, including studies with varied meth-
odologies.29 Between 1988 and 1995, reported rates of para-
sitologic (RI-RIII) resistance in children up to 15 years of age
were 2−58% for CQ and 0−4% for SP. Between 1996 and
2000, rates of parasitologic resistance in children less than five
years of age were 36−96% for CQ and 6−33% for SP. In
addition, these more recent studies reported rates of clinical
treatment failure of 10−81% for CQ and 3−25% for SP. In
2001, the Ugandan Ministry of Health replaced CQ with CQ
+ SP as first-line therapy for uncomplicated malaria.
Clinical response to antimalarial therapy involves a com-
plex interaction between the parasite, drug, and host immune
response. In this study, by restricting our analysis to children
recruited from the same target population and controlling for
age and parasite density, we were able to minimize the con-
tribution of differences in the host immune response. This
allowed us to directly compare associations between molecu-
lar markers of SP resistance and clinical response to therapy.
The use of SP combination therapy reduced the risk of ETF
compared with SP monotherapy (10% versus 1%; P < 0.001),
probably due to more rapid initial parasite clearance. Surpris-
ingly, the addition of CQ to SP did not lower the risk of LTF
compared with SP alone even after controlling for the preva-
lence of key dhfr and dhps mutations. Overall, the addition of
CQ to SP had no impact on efficacy, and CQ is clearly a poor
companion drug for SP where resistance to both drugs is
high.18,30 Of note, in a previous study from Kampala, the
prevalence of the pfcrt Thr-76 mutation (which has been
linked to CQ resistance) was 100%, suggesting the ubiquitous
nature of resistance to this drug in our patient population.31
The addition of AS to SP reduced the risk of LTF, but only in
infections with the most resistant parasites (dhfr Arg-59 +
dhps Glu-540 pure mutants). The addition of AQ to SP low-
ered the risk of LTF for all dhfr/dhps allelic risk groups, and
LTF was only associated with the dhfr Arg-59 + dhps Glu-540
pure mutant. In our patient population, the combination of
SP + AQ was the most effective regimen, but also resulted in
the strongest selective pressure for parasites most resistant to
SP because almost all treatment failures carried the dhfr Arg-
59 + dhps Glu-540 pure mutant. Thus, concern remains about
the useful therapeutic lifespan of SP +AQ in areas where
pre-existing resistance to SP is high.
In summary, field studies of molecular markers of SP re-
sistance can be useful for improving our understanding of the
determinants of the clinical response to therapy. A combina-
tion of the dhfr Arg-59 mutation (a surrogate marker of the
dhfr triple mutant) and the dhps Glu-540 mutation (a surro-
gate marker of the dhps double mutant) is the strongest pre-
dictor of treatment failure in Africa. Contrary to some prior
suggestions, in our study the dhps Glu-540 mutation played a
greater role in response to therapy than that of the dhfr Arg-
59 mutation. Since more expensive antimalarial regimens,
such as artemisinin-based combination therapy, remain be-
yond the reach of most African countries, SP combination
therapies have been adopted as first-line treatment in a num-
ber of African countries. A better understanding of the rela-
tionship between molecular markers of SP resistance and re-
sponse to therapy should help in establishing rational combi-
nation therapy policies and in estimating the useful
therapeutic life span of these regimens.
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